Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0001209191-23-007770 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-08 | 2022-02-06 | VERA | Young Joseph R | SVP, Fin, Chief Acct Offcr | P - Purchase | $7.00 | +5,714 | 22.7K | +34% | +$40.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-02-06 | P | A | 5,714 | $7.00 | 22,679 | D | — | — | (F1) Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price. (F2) Includes 817 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022. |